Review/Advances in Neurological Therapeutics (2005). Motor Neuron Disease.
|
Accession number;06A0654486
|
| Title;Review/Advances in Neurological Therapeutics (2005). Motor Neuron Disease. |
| Author;
NAITO YUTAKA
(Fac. Medicine, Mie Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.383-387(2006)
|
| Figure&Table&Reference;REF.43 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Amyotrophic lateral sclerosis (ALS) is progressive neurodegenerative disorder that predominantly affects motor neurons and is fatal within a few years of clinical onset. Until recent times, little was known about its cause and even less was available in terms of treatment. However, a considerable body of new research has greatly improved our understanding of this complex disease. To date only riluzole has been specifically approved for treatment of ALS. We discuss ALS specific pharmacotherapeutic agents, with brief outlines of the pathophysiologic processes underlying their use. We also outline some of the future directions in drug therapy that offer hope of improved outcome in this hopeless disease. Several mechanisms have been proposed to account for the progressive motor neuron death evident in ALS. These include glutamate-mediated excitotoxicity, free radical-mediated oxidative stress, neurofilament damage, neuro-inflammation and mitochondrial abnormalities. We reviewed recent advances in ALS therapy, antiglutamate agents (riluzole, memantine, galantamine), antioxidants (vit E, epigallocatechin, Zn), COX-2 inhibitor, antiapoptotic compounds, neuroprotectants (minocycline, CTRX, creatine, galectin-1), neurotrophic factors (IGF-I, BDNF, GDNF, VEGF, TGF-.BETA.2), cannabinol, RNA interference, modafinil and percutaneous radiological gastrostomy(PRG). (author abst.) |
|
|
|
Related Articles;
|
|
